Genetic alterations defining NSCLC subtypes and their therapeutic implications
about
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasisAddressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesLung Cancer Gene Signatures and Clinical PerspectivesNicotine-mediated cell proliferation and tumor progression in smoking-related cancersGene Expression Signature Differentiates Histology But Not Progression Status of Early-Stage NSCLC.Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients.The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.Recent advances in personalized lung cancer medicineLoss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer.CLCA2 as a novel immunohistochemical marker for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung.Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5.Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report.Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer.SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma.Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classificaAddressing the right targets in oncology: challenges and alternative approaches.Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer.In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.Current status of research and treatment for non-small cell lung cancer in never-smoking females.The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.Receiver operating characteristic analysis under tree orderings of disease classes.Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant.Classification of Non-Small Cell Lung Cancer Using Significance Analysis of Microarray-Gene Set Reduction Algorithm.Oncogene-Driven Metabolic Alterations in Cancer.Cell death-based treatment of lung adenocarcinoma.Liquid biopsy and its role in an advanced clinical trial for lung cancer.Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma.Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.[Advances on driver oncogenes of non-small cell lung cancer].Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes.Long non-coding RNA ZEB2-AS1 promotes proliferation and inhibits apoptosis in human lung cancer cells.Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin.Identification of subtype-specific prognostic signatures using Cox models with redundant gene elimination.
P2860
Q28069422-4F10CD3A-8F4B-4BC6-9331-87FDF3240F93Q28074716-6C2E4337-3EDA-4718-9EC1-0B8E69D00376Q28387769-D900FC78-02F6-4FA3-AE21-AB36F37514D4Q28395572-751220BB-F52C-4F43-BE1A-019B8BFA4B6BQ33611881-050597B8-7BA7-4729-828D-D9D68441C1A8Q34247934-2BF2A805-D698-4A5E-9FE3-C14444716A8CQ34252809-FF5FB771-8AB6-4E6B-BF62-2BDD5B083B42Q34404266-DC9AF7EB-3ECE-4462-9D21-2C5ACCE93B67Q34678073-6B6B9ECD-0FA1-4927-8775-5BD7C30CD381Q34680492-7B57AE55-71B5-49E1-80FC-96640D4DAB44Q34762754-744CD36F-85DC-435E-B30D-3A7C6C2E9CC0Q35434177-555000E6-EE8D-4515-BC76-DC5964373BC1Q35803501-A72FA845-4269-4294-9BBC-356DC8F4D2BCQ35957598-F15D6411-0C26-4309-8AC3-7662CA0EA80FQ36548775-B30CD2BB-92E1-4D95-B690-84575C880686Q36872186-FF385C40-B65D-45F9-BE20-709B06D6FCE9Q38329647-A9629BA0-09DB-4813-ADB7-FEC8386761F0Q38430613-7A43F9B9-4B9C-4440-86B7-58C2904F3C91Q38738104-D77295D8-7605-482F-9433-C7A5CCF84880Q38795629-6C07858A-59FB-4578-A261-E6B7A7A23C15Q38840383-C981879C-733D-4EB4-9B60-941CBEB016AAQ39298725-465955AE-143A-4B69-9CAD-677F7595F1EEQ39400469-E8B68856-7993-4BCC-959F-F41BA999B2C3Q40200918-75D13126-BD98-4124-8358-8C8A56CDCC4EQ41522586-8160DEDC-9209-498D-9C1F-A8C4B9E313E0Q41823697-446B4AD9-D72C-4B0B-8E9E-663E46219F8BQ47159555-DB7E4548-715B-445B-93DF-A322385048CDQ47711273-D6B69802-E9D2-453A-9AEA-494461699677Q48098593-85290433-E77F-48A5-9786-FF95E9C63374Q48536576-D20179A3-5505-4465-BF32-3CEF91AAA230Q49790309-4525D1D4-104A-4FB1-BC87-AE3BE57432E7Q49887912-128BE5E3-74F4-4959-B495-13A186F8FC36Q54979892-BE834312-BD09-434D-A8A1-7D5BE68C9A12Q54990183-51C48E0C-A5E2-4EC7-937A-003B34592CFAQ55068578-3514E262-4913-4E97-95AD-61916CC1F6C9Q55096489-082164C3-00DB-47D5-B758-BEC65534A02EQ55101941-90E0B8C6-055D-4415-8157-7FFE56C7937CQ55155270-E610BD7D-381D-48CC-A3A6-CDF2CD287CF5Q55318932-4D52DE29-E720-4947-9410-4F59DFC47713
P2860
Genetic alterations defining NSCLC subtypes and their therapeutic implications
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@ast
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@en
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@nl
type
label
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@ast
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@en
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@nl
prefLabel
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@ast
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@en
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@nl
P2093
P3181
P1433
P1476
Genetic alterations defining NSCLC subtypes and their therapeutic implications
@en
P2093
Larissa A. Pikor
Stephen Lam
Varune R. Ramnarine
Wan L. Lam
P304
P3181
P356
10.1016/J.LUNGCAN.2013.07.025
P407
P577
2013-11-01T00:00:00Z